RetVic

RetVic is a biotechnology company specializing in the development of next-generation viral vectors for retinal gene therapy. Spun out from the Institut de la Vision in Paris, the company utilizes a directed evolution platform to engineer Adeno-Associated Virus (AAV) capsids with enhanced transduction efficiency and specificity for retinal cell types. Their technology aims to overcome the limitations of current gene delivery systems, such as poor penetration and off-target effects, to provide more effective treatments for inherited retinal degenerations and other vision-threatening conditions. RetVic is part of the emerging ophthalmology biotech cluster in France, focusing on high-precision ocular medicine.